ArticleScientific reports2025
Risk of Alzheimer's disease and Parkinson's disease following androgen deprivation therapy in a real world nationwide cohort.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Abiraterone Acetate Affects Gene Expression Profile in a Human Male Neuronal Cell Line: Potential Mechanism for Cognitive Deficits with Prostate Cancer Therapy.Life (Basel, Switzerland) · 2026Article
- Identification of interleukin-11 as a comorbid risk factor for prostate cancer and Alzheimer's disease using integrated bioinformatics and machine learning.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The association between androgen deprivation therapy (ADT) and dementia including Alzheimer's disease remains debatable. Moreover, the evidence regarding the risk of vascular dementia and Parkinson's disease associated with ADT is limited. A population-based cohort study was conducted using the national health insurance data (2012-2022) from South Korea. Eligible patients newly diagnosed with prostate cancer who underwent ADT were compared with those who did not receive ADT. We applied propensity score matching and performed Cox proportional hazards regression analysis to calculate the adjusted hazard ratios (aHR) and 95% confidence intervals (CI). Of 163,723 patients with prostate cancer between 2013 and 2017, 24,456 were eligible. After 1:1 propensity score matching, 10,168 patients were included in each group. The risk of overall dementia was not significantly higher in ADT users compared with that of non-users (aHR = 1.07; 95% CI: 0.97-1.19); however, the elevated risk of Alzheimer's disease was observed (aHR = 1.39; 95% CI: 1.21-1.59). ADT was not associated with the risk of vascular dementia (aHR = 1.14; 95% CI: 0.70-1.94) and Parkinson's disease (aHR = 1.01; 95% CI: 0.75-1.35). Our updated evidence reinforces previous findings, indicating a positive association between ADT and the risk of Alzheimer's disease. However, it is unlikely that ADT increases the risk of vascular dementia and Parkinson's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.